A Review of Non-Nucleoside Reverse Transcriptase Inhibitors’ Structure and Activity with HIV-1 Reverse Transcriptase


The human immunodeficiency virus (HIV) weakens the body’s immune system leading to the onset of acquired immunodeficiency syndrome (AIDS). Once the progression of HIV has led to AIDS, certain infections can be severely life-threatening when they normally are not. For years, researchers have been attempting to develop a complete cure for HIV, but current treatment includes various drugs to limit the spread of the disease. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are one class of antiretroviral drugs applied to treat HIV. HIV-1, being a retrovirus, requires an enzyme, reverse transcriptase (RT), to replicate and spread throughout its host. NNRTIs act as non-competitive inhibitors, so their binding to RT causes a conformational change in the structure of the enzyme, preventing its normal function thereby stopping the virus from replicating further. Due to the more rigid “butterfly-like” structures of first-generation NNRTIs, they are less active against frequent mutations developed in drug-resistant strains of HIV-1. Second-generation NNRTIs, consisting of larger aromatic systems, are more “flexible” with further contacts with main-chain residues or other residues in the NNRTI binding pocket, so they are more successful. NNRTIs have ranged from large systems to small chains, and the interactions and design intentions are important to understand for the creation of stronger inhibitors. The purpose of this article is to explore the structure and function of first, second, and new generations of NNRTIs against RT.


The HIV virus affects people across the globe, including in 3rd world countries where it is difficult for people to access treatment options. Therefore, the pursuit of treatment options for this retrovirus proves significant. It is estimated that 37.9 million people have HIV as of 2019.[1]

Without treatment, the virus spreads and weakens the immune system of the host because it infects and damages CD4+ T cells, which are part of the immune system. CD4+ are those cells that regulate and suppress the immune system response. HIV can replicate billions of times a day, which quickly impairs an individual’s immune system and leads to acquired immune deficiency syndrome (AIDS). People infected with HIV/AIDS can develop opportunistic illnesses (OIs) and cancers that would not grow in an uninfected person. These illnesses are known as AIDS-defining illnesses because they can only infect the host if the host’s immune system is severely weakened.[2] Some AIDS-defining illnesses and cancers can even be fatal and are the main cause of death for HIV-infected patients.[3]

Treatment for HIV generally includes a regimen with multiple and different types of drugs to attack the virus at different stages in its life cycle, known as highly active antiretroviral therapy (HAART). Non-nucleoside reverse transcriptase inhibitors specifically block the function of the reverse transcriptase (RT) enzyme of HIV-1. This enzyme converts HIV’s viral RNA into DNA, which then allows the virus to infect the host’s DNA and then spread through the body. RT is a key enzyme for HIV replication, so it is a common target for anti-HIV drugs. NNRTIs inhibit RT by binding to an allosteric site on the enzyme, called the NNRTI “binding pocket” or (NNRTI-BP). This then causes a conformational change in the shape of the enzyme, which prevents it from carrying out its role in the transcription of viral RNA to DNA. NNRTIs have a wide range of structures with unique binding modes because the NNRTI-BP is in a closed conformation. Only once an NNRTI is bound to the RT enzyme does the binding “pocket” exist, so each ligand forms slightly different interactions with the amino acid residues.[4]

Among the FDA-approved NNRTIs, there are several generations of NNRTIs from different drug classes. (From here on, all NNRTIs referenced as part of the first or second generation include only FDA-approved NNRTIs). The first-generation NNRTIs are nevirapine, efavirenz, and delavirdine, which are characterized by their “butterfly-like” conformation when bound to RT.[5] Second-generation NNRTIs are far more potent against resistant strains of HIV-1, including rilpivirine and delavirdine. Then, investigational drugs, part of the next generation of NNRTIs, have structural features that interact well with the NNRTI binding pocket, which could be used to develop better analogs. Still, the great number of resistant HIV-1 RTs requires stronger, more potent NNRTIs for treatment, and other anti-HIV compounds that target RT are also used in conjunction with NNRTIs for more effective treatment.

  1. HIV-1 RT and the NNRTI “binding pocket”

HIV Lifecycle

Retroviruses are a class of viruses that use the host cell’s machinery to replicate their proteins and RNA and proliferate. HIV infects CD4 cells, or T-cells, in the immune system. The virus attacks a T-cell and then uses the cell to manufacture and release more viruses into the body through the bloodstream.

The seven steps of the life cycle of HIV are

1) binding, 2) fusion, 3) reverse transcription, 4) integration,

5) replication, 6) assembly 7) budding (figure 9).


The HIV virus itself, includes the virus’s DNA and associated enzymes within a protein coat, or a capsid. First, HIV binds to the receptor, glycoprotein 41 (GP41) on the CD4 cell, which then facilitates fusion between the cell and the virus.

After the virus enters the cell, it initiates reverse transcription to convert its single-stranded RNA (ssRNA) into double-stranded DNA (dsDNA) using HIV’s reverse transcriptase enzyme. RT makes an abnormal amount of mistakes during transcription; 1 in every 2000 base pairs is miscopied, approximately 0.05%. The high rate of mutation is an advantage to HIV since it can easily and quickly mutate, conferring resistance to NRTI and NNRTI drugs if given independently.[6]

Antiretroviral therapy (ART) involves administering one drug, an anti-HIV medication, to treat HIV. Highly active antiretroviral therapy (HAART), which includes administering 3 or more antiretroviral drugs, like NRTIs and NNRTIs, is more effective since it is more difficult for HIV to evade many antiretroviral medicines at once.[4, 7]

Again, reverse transcription produces viral dsDNA. Then, the HIV integrase enzyme integrates the viral DNA into the CD4 cell’s DNA. The cell naturally transcribes the HIV DNA into multiple copies of new HIV RNA, and some copies of the RNA are translated to make viral proteins while another viral RNA becomes part of the new virus’s genome. These viral proteins and new HIV RNA assemble into immature viruses at the surface of the cell. They leave the CD4 cell through a process called budding, killing the healthy cell. The virus later matures outside the host cell and infects other cells. [8, 9, 10]

Figure 9: HIV life cycle (Created with

NNRTI Binding Pocket

The heterodimeric HIV-1 RT enzyme (figure 10) consists of a p66 (66 kDa) subunit and a p51 (51 kDa) subunit. The p66 chain consists of multiple, flexible subdomains, likened to a hand, allowing RT to take on different conformational states to bind nucleic acid template strands, and the p51 chain provides structural support for p66.[11]

All NNRTIs interact with RT by binding to an allosteric site on the p66 subunit of RT to non-competitively inhibit reverse transcription of the HIV-1 RNA.[12] This site is called the non-nucleoside reverse transcriptase inhibitor binding “pocket” or the NNRTI-BP (figure 11). The NNRTI-BP’s residues create hydrogen bonding interactions, hydrophobic contacts, and π-π stacking interactions with NNRTIs at hydrophobic residues (K101, K103, S105, D192, and E224 of the p66 subunit and E138 of the p51 subunit) and with the aromatic residues (Y181, Y188, F227, W229, and Y232).[13] The NNRTI-BP is flexible, adopting different conformations for different NNRTIs that bind to RT, such as the butterfly-like and horseshoe-like geometries. These create short-range and long-range distortions of the RT structure that result in RT inhibition.[14]

Because NNRTI binding results in multiple structural and conformational changes, it is unclear which of these conformational changes is operative in RT inhibition. We present two of the possible factors in the mechanism of inhibition of RT by NNRTIs: a change in direction of the p66 thumb or loss in mobility and distortion of the primer grip. The binding of an NNRTI may affect the direction or degree of mobility that the p66 “thumb” subdomain possesses. A molecular dynamics study supports the theory that NNRTI binding restricts the mobility of the thumb subdomain, also known as the “arthritic model.”[15] However, other computational studies suggest that NNRTI binding may not restrict mobility, and instead change the direction that the thumb subdomain can move. NNRTI binding may induce the restriction of p66 thumb mobility by changing the residues which make up the primer grip, preventing proper positioning of the primer 3’ end of nucleic acids in the polymerase active site.[11, 14] NNRTI binding limits p66 mobility and therefore distorts the “primer grip”, which prevents RNA or DNA from binding to the enzyme.[13]

Figure 10: HIV-1 reverse transcriptase (PDB: 1REV) visualized in ChimeraX with the p66 subunit in purple and p51 subunit in pink.

(Ren, et al. “The Structure of HIV-1 Reverse Transcriptase Complexed with 9-Chloro-TIBO: Lessons for Inhibitor Design.” Structure 3, no. 9 (1995).)

Figure 11: Nevirapine, in blue, docked in NNRTI-BP, circled in yellow, on HIV-1 RT (PDB: 1REV) using Autodock Vina and visualized in ChimeraX.


        2.First Generation NNRTIs

Each NNRTI creates interactions with different amino acids due to their differences in structure and molecular makeup. A key feature of first-generation NNRTIs is their “butterfly-like” conformation when bound to RT (figure 1); compounds possessing this structure have been shown to be particularly effective for inhibition of HIV-1 RT. This butterfly-like geometry when bound is supported by the structure of the NNRTI, which usually has a hydrophilic center and two hydrophobic moieties, which resemble the “body” and “wings”, respectively. One of the wings is a heteroaromatic ring and the other is usually a phenyl or allyl substitute.[11] NNRTIs sterically inhibit the rigid motion between the thumb and palm subregions of the p66 subunit of the RT enzyme. This first-generation of NNRTIs are effective against wild type (WT) HIV-1, but their potency dramatically decreases when used with mutant HIV-1 RTs.[16] The rapid emergence of mutations in HIV-1 RT is a problem in NNRTI development because these mutations confer resistance to current drugs. HIV-1 easily mutates to evade first-generation NNRTIs, especially when taken individually. Cross-resistance, which occurs when a virus is immune to the effect of one molecule because of exposure to a similar molecule in the past, is also a common reason for treatment failure and is part of the reason why HIV can evade many first-generation NNRTIs through one mutation.[14, 17, 18]

Figure 1: “Butterfly-like” geometry of first-generation NNRTIs

Nevirapine (NVP)

Nevirapine (figure 2) was the first NNRTI approved for HIV treatment. It has a very visible butterfly conformation, seen in its dipyridodiazepino structure, with three joined nitrogen heterocycles that are colored green. Its methyl group and cyclopropyl group aid in creating hydrophobic contacts.

Figure 2: Chemical structure and 3d modeled structure of nevirapine and binding interactions of nevirapine in NNRTI-BP (PDB: 4PUO)

The heteroaromatic ring has a functional group that can be both an electron donor and acceptor, which interacts with the main chain K101 and K103. The binding of nevirapine disrupts the reverse transcriptase’s DNA polymerization activity by forming a pocket in the enzyme. Pocket formation prevents the ability of reverse transcriptase to add nucleotides and translocate.[19, 20]


Efavirenz (EFV) is one of the first-generation NNRTIs that serve as the first line of the regiment for HIV-1. Its structure (figure 3) still has a butterfly conformation and its overall structure is a benzoxazine.

Figure 3: Chemical structure and 3d modeled structure of efavirenz and binding interactions of efavirenz in NNRTI-BP (PDB: 1FK9)

In comparison to NRTI therapy, efavirenz has proven to be more efficient. Despite higher efficiency, a single mutation on the reverse transcriptase of the virus is sufficient to confer resistance towards the drug, including the K103N mutation. Aside from mutations inducing this resistance and affecting the efficiency of efavirenz, the drug has also shown side effects affecting the central nervous system.[18, 21]


Delavirdine (figure 4) also resembles a butterfly structure consisting of two main structures, an indole and pyridine nucleus. These two heterocyclic components have been identified as having important anti-HIV activity, and have led to the development of more novel inhibitors.[22] Because its efficacy is relatively weak compared to other inhibitors, it is mostly used in conjunction with other inhibitors in treatment.[22]

Figure 4: Chemical structure and 3d modeled structure of delavirdine and binding interactions of delavirdine in NNRTI-BP (PDB: 1KLM)

       3.Second Generation NNRTIs

In comparison to first-generation NNRTIs, second-generation NNRTIs have achieved high levels of inhibition even when tested against mutated HIV-1 strains.[13] This is because greater contacts are formed with residues that are less susceptible to becoming mutated side-chains. Further, the smaller size and torsional flexibility of second-generation NNRTIs contribute to their greater ability to adapt to mutations in the binding pocket. The structures of second-generation NNRTIs are part of the class of diaryl pyrimidines (DAPY) compounds. Specifically, second-generation compounds have unique horseshoe-like binding mode as opposed to the butterfly-like conformation of first-generation NNRTIs.[23] It is important to note that second-generation NNRTIs are still allosteric inhibitors and bind to the same binding pocket as first-generation NNRTIs, although they have different modes of binding.

Etravirine (ETV)

Etravirine (figure 5) provided very strong inhibitory results compared to first-generation NNRTIs. The molecule displayed promising activity not only on HIV-1 RT but also on HIV-2 RT, activity which was not present in the first-generation substrate. It is a DAPY and aromatic ether containing three heterocyclic rings, a central diaminopyrimidine with substituted bromine, and two aromatic rings with a cyano group.[24]

Etravirine’s flexibility allows it to sustain activity even against the mutations that have prevented first-generation NNRTIs from functioning, specifically, L100I and K103N.

Figure 5: Chemical structure and 3d modeled structure of etravirine and binding interactions of etravirine in NNRTI-BP (PDB: 3MEC)


Rilpivirine (figure 6), initially known as TMC-278, is among the second generation of NNRTIs that have demonstrated greater genetic barriers to resistance conferred by mutations.[25] Key components of its DAPY structures are its aromatic rings, multiple methyl side chains, aniline ring, and cyano groups. Rilpivirine’s aniline ring and cyanovinyl group form a flexible dihedral angle, allowing for torsional flexibility in the binding pocket. A more flexible ligand suggests not only greater potency, but a greater genetic barrier of resistance from reverse transcriptase, which has been supported by increased activity shown by rilpivirine with mutations L100I, K103N, Y181C, and Y181L.[26]

Figure 6: Chemical structure and 3d modeled structure of rilpivirine and binding interactions of rilpivirine in NNRTI-BP (PDB:2ZD1)

When analyzing the crystal structure of rilpivirine bound in mutant RT, the cyanovinyl group is observed to have strong interactions with Y183 following the very common Y181C mutation. The various crystal structures of rilpivirine with different mutations on RT show different conformations of the ligand in the binding pocket, but still with strong inhibitory effects. This highlights the importance of torsional flexibility to maintain resistance to mutations.

      4. Further Structures

Although the first two generations of NNRTIs have been relatively successful in inhibiting HIV and decreasing the viral load when multiple drugs are used in treatment, there are several new schemes and structures for further generations of NNRTIs.


Levirisine (figure 7) has a much more unconventional structure compared to NNRTIs in the first two generations. The structure is centered around a substituted pyrazole ring joined to a six-membered aromatic ring by a central ether. The presence of only one aromatic ring may limit the strength of possible π-π stacking interactions, a type of weak chemical bond, between the ligand and the reverse transcriptase enzyme. However, the design of this comparatively less bulky ligand would allow for greater flexibility in the binding pocket. Greater flexibility is important in the inhibition of mutated HIV-1 reverse transcriptase, which is a significant problem. Additionally, ethyl carbon chains attached to the pyrazole allow for hydrophobic interactions in the binding pocket, creating a more favorable binding affinity. Cyano groups on aromatic rings are present in other third-generation NNRTIs as well as both second-generation NNRTIs, etravirine, and rilpivirine. The structure is designed to minimize interactions with the portions of the binding pocket that are prone to mutations while maximizing contacts with the amino acids that are not prone to mutations. This design mindset contrasts with other NNRTIs that have a much greater molecular weight and aim for stronger interactions by creating a larger contact area. Further, lersivirine showed inhibitory activity when tested against 14 out of 15 strains of HIV-1 RT that were mutated at a single amino acid in the binding pocket. When lersivirine was tested with NRTI drugs, synergistic interactions were observed. Overall, the molecule shows promise for inhibiting RT and this new pharmacophore of smaller ligands provides new insights for designing NNRTIs.[27]

Figure 7: Chemical structure and 3d modeled structure of lersivirine and binding interactions of lersivirine in NNRTI-BP (PDB: 2WOM)

*Analysis of the crystal structure of Lersivirine, when bonded to HIV-1 RT, shows interactions with L100, V106, Y181, Y188, F227, W229, Y318, L234, and P236. Specifically, with Y181, Lersivirine creates a significant conformational change in the amino acid, similar to the change created by efavirenz. Two hydrogen bonds are formed between the ligand and L103 and P236.

Calanolide A

Calanolide A (figure 8), being a natural product that was extracted from plants in a Malaysian rainforest, is arguably the most unique NNRTI. It is an organic tetracyclic heterocycle compound. The structure of these NNRTIs is what determines their activity and an important understanding with the Calanolide family is that they interact with reverse transcriptase in a mechanically different way. They are a mixed type inhibitor and do show activity when coupled with HIV-1 reverse transcriptase.

The diversity of NNRTIs and specifically the calanolide family of inhibitors compared to either of the past generations displays the variety of molecules in the NNRTI family. Although calanolide A is comparatively less potent than the other generations of NNRTIs, it showed very promising activity when inhibiting reverse transcriptase with a mutation at Y181. There is also evidence that the Calanolide class binds not only to the NNRTI-BP but also to another binding pocket, which could lead to greater inhibition when coupled with other NNRTIs. [28]

Figure 8: Structure of calanolide A visualized in Avogadro



The high mutation rate of HIV-1 RT necessitates the development of anti-HIV compounds. The future of HIV treatment firmly lies in the expansion of knowledge on novel NNRTIs. Yet another important area of emphasis is “synergistic inhibition”. This is attained through a combination of NNRTI and nucleoside reverse transcriptase inhibitor (NRTI) drugs. NRTIs bind competitively to RT, directly at the active site, also inhibiting the enzyme, whereas NNRTIs are non-competitive inhibitors. Multiple drugs, like both NNRTIs and NRTIs, are used to treat HIV in a patient, referred to as polypharmacy. Although polypharmacy is used in HIV treatment, it is arguable that the usage is not ideal and rather problematic. 55% of people 50 years and older took 5 or more daily medications for HIV.[24] This excessive polypharmacy is not ideal as it can result in nonadherence and adverse drug events.[20, 29]

There is also a one-pill ART option known as ADONE (adherence to one pill) that combines multiple antiretroviral drugs into one pill that increases adherence and quality of life on average. It also improves CD4+ cell count as decreasing viral RNA production. Especially with chronic, asymptomatic diseases such as HIV, adherence is poor, which increases the risk of cardiovascular disease and the resistance of HIV to the medication.[30] The method of accomplishing this is to have drugs that are effective at targeting specific parts of the enzyme as the process of interference is observed when drugs attempt to attack the same binding spot. NRTIs function by mimicking DNA nucleotides, and therefore bind to the binary RT:DNA complex. Hence, an NNRTI that can precisely interact with the RT:DNA:dNTP complex is likely to be most ideal for synergistic inhibition.[31] Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones are examples of drugs that have been shown to be promising in this regard.[32] Hence, further research should be conducted regarding them.



HIV is a retrovirus, a class of viruses that use the reverse transcriptase enzyme to synthesize double-stranded DNA from single-stranded RNA. They then integrate the viral DNA into a host cell’s genome to produce more viruses. Antiretroviral drugs prevent the proliferation of HIV by inhibiting the entry and/or reverse transcription of HIV so that the virus cannot replicate. One class of antiretroviral drugs are NNRTIs, also known as non-nucleoside reverse transcriptase inhibitors. NNRTIs non-competitively inhibit the RT enzyme by binding to the NNRTI-BP and changing the short-range and long-range conformation of RT and distorting the palm and thumb subregions of RT. First-generation NNRTIs, which are less effective than second-generation NNRTIs, inhibit the motion of the palm and thumb subregions of the p66 unit. HIV mutates to the rigid structure of first-generation NNRTIs, so they are no longer effective. Second-generation NNRTIs have a similar mechanism of action, but are more flexible and therefore are more effective. HAART and ADONE (ADherence to ONE pill), which use 3-4 ARVs, are used to minimize the chance that HIV will mutate by targeting many sites of entry or replication, therefore reducing the viral load. NNRTIs, especially the second generation, inhibit RT more effectively and for longer because of their flexibility.

Funding Statements/Acknowledgments

We would like to recognize our advisor Mr. Edward Njoo for his guidance and support in writing this paper.



  1. Published: Sep 09, 2019. “The Global HIV/AIDS Epidemic.” KFF, September 30, 2019. (accessed January 11, 2020).
  2. “Comprehensive, up-to-Date Information on HIV/AIDS Treatment and Prevention from the University of California San Francisco.” Opportunistic Infections and AIDS-Related Cancers, September 14, 2011. (accessed January 17, 2020).
  3. “ Veterans Affairs. Just Diagnosed” AIDS-defining illnesses, June 21, 2005. (accessed January 17, 2020).
  4. Das, Kalyan, Paul J. Lewi, Stephen H. Hughes, and Eddy Arnold. “Crystallography and the Design of Anti-AIDS Drugs: Conformational Flexibility and Positional Adaptability Are Important in the Design of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.” Progress in Biophysics and Molecular Biology 88, no. 2 (June, 2005): 209–31.

  5. Chen, Xuwang, Peng Zhan, Dongyue Li, Erik De Clercq, and Xinyong Liu. “Recent Advances in DAPYs and Related Analogues as HIV-1 NNRTIs.” Current Medicinal Chemistry 18, no. 3 (2011): 359–76.
  6. Ghosn, Jade, Marie-Laure Chaix, and Constance Delaugerre. “HIV-1 Resistance to First- and Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors.” AIDS Reviews 11, no. 3 (September 2009): 165–73.
  7. Ivetac, Anthony, and J. Andrew Mccammon. “Elucidating the Inhibition Mechanism of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors through Multicopy Molecular Dynamics Simulations.” Journal of Molecular Biology 388, no. 3 (2009): 644–58.
  8. Sharp, Paul M., and Beatrice H. Hahn. “The Evolution of HIV-1 and the Origin of AIDS.” Philosophical Transactions of the Royal Society B: Biological Sciences 365, no. 1552 (2010): 2487–94.
  9. Melikyan, Gregory B. “HIV Entry: a Game of Hide-and-Fuse?” Current Opinion in Virology 4 (2014): 1–7.
  10. Hu, W.-S., and S. H. Hughes. “HIV-1 Reverse Transcription.” Cold Spring Harbor Perspectives in Medicine 2, no. 10 (2012).
  11. Das, Kalyan, and Eddy Arnold. “HIV-1 Reverse Transcriptase and Antiviral Drug Resistance. Part 1.” Current Opinion in Virology 3, no. 2 (2013): 111–18. 
  12. De Clercq, Erik. “Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future.” Chemistry & Biodiversity 1, no. 1 (2004): 44–64.
  13. Sluis-Cremer, Nicolas, N. Temiz, and Ivet Bahar. “Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding.” Current HIV Research 2, no. 4 (October, 2004): 323–32.
  14. Hsiou, Y, J Ding, K Das, Jr Ad Clark, Sh Hughes, and E Arnold. “Structure of Unliganded HIV-1 Reverse Transcriptase at 2.7 å Resolution: Implications of Conformational Changes for Polymerization and Inhibition Mechanisms.” Structure 4, no. 7 (July 15, 1996): 853–60.

  15. Seckler, James M., Mary D. Barkley, and Patrick L. Wintrode. “Allosteric Suppression of HIV-1 Reverse Transcriptase Structural Dynamics upon Inhibitor Binding.” Biophysical Journal 100, no. 1 (2011): 144–53.
  16. Namasivayam, Vigneshwaran, Murugesan Vanangamudi, Victor  G. Kramer, Sonali Kurup, Peng  Zhan, Xinyong Liu, Jacob  Kongsted, and Siddappa  N. Byrareddy. “The Journey of HIV1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.” Journal of Medicinal Chemistry 62 , no. 10 (December 5, 2018): 4851–83.
  17. Kohlstaedt, L., J Wang, J. Friedman, P. Rice, and T. Steitz. “Crystal Structure at 3.5 A Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor.” Science 256, no. 5065 (1992): 1783–90.

  18. Mbuagbaw, Lawrence, Sara Mursleen, James H Irlam, Alicen B Spaulding, George W Rutherford, and Nandi Siegfried. “Efavirenz or Nevirapine in Three-Drug Combination Therapy with Two Nucleoside or Nucleotide-Reverse Transcriptase Inhibitors for Initial Treatment of HIV Infection in Antiretroviral-Naïve Individuals.” Cochrane Database of Systematic Reviews, October 10, 2016.
  19. Das, Kalyan, and Eddy Arnold. “HIV-1 Reverse Transcriptase and Antiviral Drug Resistance. Part 2.” Current Opinion in Virology 3, no. 2 (2013): 119–28.
  20. Buscher, A, C Hartman, M A Kallen, and T P Giordano. “Impact of Antiretroviral Dosing Frequency and Pill Burden on Adherence among Newly Diagnosed, Antiretroviral-Naïve HIV Patients.” International Journal of STD & AIDS 23, no. 5 (May 23, 2012): 351–55.
  21. Rakhmanina, Natella Y, and John N Van Den Anker. “Efavirenz in the Therapy of HIV Infection.” Expert Opinion on Drug Metabolism & Toxicology 6, no. 1 (January 6, 2010): 95–103.
  22. Behja, Wollela, and Mudin Jemal. “Anti-HIV Drug Discovery, Development and Synthesis of Delavirdine: Review Article.” International Research Journal of Pure and Applied Chemistry, 2019, 1–16.
  23. Lansdon, Eric B., Katherine M. Brendza, Magdeleine Hung, Ruth Wang, Susmith Mukund, Debi Jin, Gabriel Birkus, Nilima Kutty, and Xiaohong Liu. “Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design.” Journal of Medicinal Chemistry 53, no. 10 (2010): 4295–99.
  24. Best, Brookie M, and Miguel Goicoechea. “Efavirenz – Still First-Line King?” Expert Opinion on Drug Metabolism & Toxicology 4, no. 7 (2008): 965–72.
  25. Das, K., J. D. Bauman, A. D. Clark, Y. V. Frenkel, P. J. Lewi, A. J. Shatkin, S. H. Hughes, and E. Arnold. “High-Resolution Structures of HIV-1 Reverse Transcriptase/TMC278 Complexes: Strategic Flexibility Explains Potency against Resistance Mutations.” Proceedings of the National Academy of Sciences 105, no. 5 (2008): 1466–71.
  26. Dobson, E. L.; Luque, A. E. Rilpivirine. (accessed Jan 16, 2020)
  27. Corbau, Romuald, Julie Mori, Chris Phillips, Lesley Fishburn, Alex Martin, Charles Mowbray, Wendy Panton, et al. “Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1.” Antimicrobial Agents and Chemotherapy 54, no. 10 (July 26, 2010): 4451–63.
  28. Buckheit, Robert W., E. Lucile White, Valerie Fliakas-Boltz, Julie Russell, Tracy L. Stup, Tracy L. Kinjerski, Mark C. Osterling, Ann Weigand, and John P. Bader. “Unique Anti-Human Immunodeficiency Virus Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Calanolide A, Costatolide, and Dihydrocostatolide.” Antimicrobial Agents and Chemotherapy 43, no. 8 (January 1999): 1827–34.
  29. Edelman, E. Jennifer, Kirsha S. Gordon, Janis Glover, Ian R. Mcnicholl, David A. Fiellin, and Amy C. Justice. “The Next Therapeutic Challenge in HIV: Polypharmacy.” Drugs & Aging 30, no. 8 (June 6, 2013).
  30. Maggiolo, Franco, Monica Airoldi, Mauro Zaccarelli, Luca Bisi, Teresa Bini, Andrea Antinori, Cristina Mussini, et al. “One-Pill Once-a-Day HAART: a Simplification Strategy That Improves Adherence and Quality of Life of HIV-Infected Subjects.” Patient Preference and Adherence, 2010, 115.
  31. Das, Kalyan, Sergio E Martinez, Joseph D Bauman, and Eddy Arnold. “HIV-1 Reverse Transcriptase Complex with DNA and Nevirapine Reveals Non-Nucleoside Inhibition Mechanism.” Nature Structural & Molecular Biology 19, no. 2 (January 22, 2012): 253–60.
  32. Campiani, Giuseppe, Vito Nacci, Isabella Fiorini, Maria P. De Filippis, Antonio Garofalo, Giovanni Greco, Ettore Novellino, Sergio Altamura, and Laura Di Renzo. “Pyrrolobenzothiazepinones and Pyrrolobenzoxazepinones:  Novel and Specific Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Antiviral Activity.” Journal of Medicinal Chemistry 39, no. 14 (1996): 2672–80.

About the Author

The authors of this paper, Anvi Surapaneni, Atri Surapaneni, Ananya Vittaladevuni, and Rohan Adwankar are all student researchers at the Center for Advanced Study in Fremont. They have worked on researching potential anti-HIV compounds together.

Leave a Reply

Your email address will not be published. Required fields are marked *